← Back to Search

Reslizumab for Sinusitis

Phase 3
Waitlist Available
Led By Joshua Jacobs, MD
Research Sponsored by Joshua S. Jacobs
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Pivotal Trial

Summary

This trial is testing Reslizumab, a medication that helps reduce inflammation, to see if it is effective for people with chronic sinusitis. Chronic sinusitis is a long-term condition where the sinuses are swollen and inflamed. Reslizumab works by blocking certain proteins that cause this inflammation, aiming to reduce the swelling and improve symptoms.

Eligible Conditions
  • Sinusitis
  • Sinus Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2014 Phase 3 trial • 489 Patients • NCT01287039
38%
Asthma
16%
Upper respiratory tract infection
11%
Nasopharyngitis
9%
Sinusitis
8%
Headache
7%
Influenza
5%
Oropharyngeal pain
5%
Bronchitis
5%
Urinary tract infection
5%
Back pain
5%
Rhinitis allergic
4%
Cough
4%
Pharyngitis
2%
Dizziness
1%
Pneumonia
1%
Chest pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Reslizumab 3.0 mg/kg

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ReslizumabExperimental Treatment1 Intervention
Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Reslizumab
FDA approved

Find a Location

Who is running the clinical trial?

Joshua S. JacobsLead Sponsor
Joshua Jacobs, MDPrincipal InvestigatorAllergy and Asthma Clinical Research
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top